Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACX Care: Extremecare for Hand-Foot Syndrome Prevention
NCT04833998Phase 2Unknown
- Sponsor
- IBCC Oncologia
- Start
- Aug 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Extremecare in hand-foot syndrome (HFS), sponsored by IBCC Oncologia. Status: unknown.
02
Drugs
Extremecare
03
Conditions
hand-foot syndrome (HFS)
Beyond the preview
Go deeper on NCT04833998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833998.